These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 36082178)

  • 21. A young girl with refractory intestinal Behçet's disease: a case report and review of literatures on pediatric cases who received an anti-tumor necrosis factor agent.
    Watanabe S; Aizawa-Yashiro T; Tsuruga K; Kinjo M; Ito E; Tanaka H
    Rheumatol Int; 2013 Dec; 33(12):3105-8. PubMed ID: 23266507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-TNF therapy in the management of ocular attacks in an elderly patient with long-standing Behçet's disease.
    Karube H; Kamoi K; Ohno-Matsui K
    Int Med Case Rep J; 2016; 9():301-304. PubMed ID: 27729816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mucosal healing in intestinal Behçet's disease: A systematic review and meta-analysis.
    Gong L; Zhang YL; Sun LX; Chen GR; Wu D
    J Dig Dis; 2021 Feb; 22(2):83-90. PubMed ID: 33314672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term clinical outcomes of intestinal Behçet's disease: A 30-year cohort study at a tertiary hospital in South Korea.
    Park J; Park SJ; Park JJ; Kim TI; Cheon JH
    J Gastroenterol Hepatol; 2023 Mar; 38(3):386-392. PubMed ID: 36346041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients.
    Vallet H; Riviere S; Sanna A; Deroux A; Moulis G; Addimanda O; Salvarani C; Lambert M; Bielefeld P; Seve P; Sibilia J; Pasquali J; Fraison J; Marie I; Perard L; Bouillet L; Cohen F; Sene D; Schoindre Y; Lidove O; Le Hoang P; Hachulla E; Fain O; Mariette X; Papo T; Wechsler B; Bodaghi B; Rigon MR; Cacoub P; Saadoun D;
    J Autoimmun; 2015 Aug; 62():67-74. PubMed ID: 26162757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
    Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
    Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.
    Park J; Cheon JH
    Gut Liver; 2018 Nov; 12(6):623-632. PubMed ID: 29788675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment and outcomes: medical and surgical treatment for intestinal Behçet's disease.
    Hisamatsu T; Hayashida M
    Intest Res; 2017 Jul; 15(3):318-327. PubMed ID: 28670228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intestinal Behçet's disease appearing during treatment with adalimumab in a patient with ankylosing spondylitis.
    Chung SH; Park SJ; Hong SP; Cheon JH; Kim TI; Kim WH
    World J Gastroenterol; 2013 Aug; 19(32):5389-92. PubMed ID: 23983446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effectiveness of the anti-tumor necrosis factor therapy infliximab in neuro-Behçet's disease: a systematic review and meta-analysis.
    Mohammed RHA; Woldeamanuel YW
    J Int Med Res; 2023 May; 51(5):3000605231169895. PubMed ID: 37203384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-Term Efficacy of Adalimumab in Patients With Intestinal Behcet's Disease: Eight Consecutive Cases.
    Tanida S; Mizoshita T; Nishie H; Ozeki K; Katano T; Shimura T; Kubota E; Kataoka H; Kamiya T; Joh T
    J Clin Med Res; 2016 Apr; 8(4):334-7. PubMed ID: 26985255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and safety of adalimumab in patients with intestinal Behçet's disease: a real-world prospective observational study in South Korea.
    Yu J; Shin SJ; Park YJ; Kim HW; Lee BI; Ye BD; Kim GT; Kim SK; Kim JS; Kim YH; Jeong S; Cheon JH
    BMC Gastroenterol; 2023 Dec; 23(1):449. PubMed ID: 38114956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease.
    Iwata S; Saito K; Yamaoka K; Tsujimura S; Nawata M; Hanami K; Tanaka Y
    Mod Rheumatol; 2011 Apr; 21(2):184-91. PubMed ID: 21052764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-Term Outcomes and Predictors of Sustained Response in Patients with Intestinal Behcet's Disease Treated with Infliximab.
    Zou J; Ji DN; Cai JF; Guan JL; Bao ZJ
    Dig Dis Sci; 2017 Feb; 62(2):441-447. PubMed ID: 28044230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A case of intestinal Behçet's disease treated with infliximab monotherapy who successfully maintained clinical remission and complete mucosal healing for six years.
    Maruyama Y; Hisamatsu T; Matsuoka K; Naganuma M; Inoue N; Ogata H; Iwao Y; Kanai T; Hibi T
    Intern Med; 2012; 51(16):2125-9. PubMed ID: 22892489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IL-6 blockade for Behçet's disease: review on 31 anti-TNF naive and 45 anti-TNF experienced patients.
    Arida A; Saadoun D; Sfikakis PP
    Clin Exp Rheumatol; 2022 Sep; 40(8):1575-1583. PubMed ID: 36106545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Interleukin-23R Gene Polymorphisms with Behcet's Disease Susceptibility: A Meta-Analysis of Case-control Studies.
    Gong HB; Wu XJ; Pu XM; Kang XJ
    Immunol Invest; 2020 Aug; 49(6):648-661. PubMed ID: 31814470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature.
    Hatemi I; Hatemi G; Pamuk ON; Erzin Y; Celik AF
    Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S129-37. PubMed ID: 26486925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
    Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
    Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Two patients with childhood-onset Behcet's disease successfully treated by anti-tumor necrosis factor therapy].
    Kaneko U; Kishi T; Kikuchi M; Hara R; Shinoki T; Miyamae T; Imagawa T; Mori M; Yokota S
    Nihon Rinsho Meneki Gakkai Kaishi; 2010; 33(3):157-61. PubMed ID: 20601837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.